Group 1 - Brendan, a Pennsylvanian, completed a Ph.D. at Stanford University in organic synthesis in 2009 [1] - He worked for Merck, a major pharmaceutical company, from 2009 to 2013 [1] - Brendan has experience in biotech, including startups like Theravance and Aspira, before joining Caltech [1] - He was the first employee and co-founder of 1200 Pharma, which spun out of Caltech and secured significant investment in the 8 figures [1] - Brendan remains an avid investor, focusing on market trends, particularly in biotechnology stocks [1]

Core Insights - The article highlights the background and achievements of Brendan, a key figure in the biotechnology sector, emphasizing his academic credentials and professional experience in both pharmaceutical and biotech industries [1]. Group 1: Background and Education - Brendan completed a Ph.D. in organic synthesis at Stanford University in 2009 [1]. - He worked for Merck, a major pharmaceutical company, from 2009 to 2013 [1]. Group 2: Professional Experience - Brendan has experience in biotech, including roles in startups such as Theravance and Aspira before joining Caltech [1]. - He was the first employee and co-founder of 1200 Pharma, which spun out of Caltech and secured significant investment in the eight-figure range [1]. Group 3: Investment Focus - Brendan remains an avid investor, particularly focused on market trends and biotechnology stocks [1].

分组1 - The Fed is set to announce its rate decision on Wednesday at 2 PM, followed by PPI numbers on Thursday morning [2] - Small-cap stocks show high short interest, with the median Russell 2000 stock at 5.5% of its market cap, significantly higher than Nasdaq-100 at 2.5% and S&P 500 at 2.4%, which is the highest in 7 years [4] - TSLA is in a historically bullish window, with nine of the last ten years showing an average gain of +3.7% during this period [6] 分组2 - ORCL is expected to report earnings this week, but there is uncertainty as earnings outcomes are seen as a 50/50 proposition [7] - Other companies of interest include ROKU, CIFR, NVDA, EOSE, and NXT, which are being considered for potential investment [7]

Core Insights - The article outlines key events in the U.S. stock market for the week of November 2 to November 7, 2025, including significant earnings reports and economic indicators [2]. Group 1: Economic Indicators - On November 3, the U.S. will release the October ISM Manufacturing PMI [2]. - On November 5, the October ISM Non-Manufacturing PMI will be published [2]. Group 2: Earnings Reports - Pre-market earnings reports on November 3 include companies such as CIFR, ON, PFE, RACE, VITL, and NCLH [2]. - Post-market earnings reports on November 3 include PLTR, FN, BWXT, HIMS, AXON, PINS, UPST, SMCI, BYND, MARA, KGC, NVTS, and GRAB [2]. - Pre-market earnings reports on November 5 include CCJ, U, NVO, RXRX, MCD, and SRAD [2]. - Post-market earnings reports on November 5 include HOOD, APP, LEU, IONQ, and FIG [2]. - Pre-market earnings reports on November 6 include VST, QBTS, DDOG, AZN, WBD, DUOL, ARM, QCOM, SNAP, and ELF [2]. - Post-market earnings reports on November 6 include SNDK, IREN, SOUN, ACHR, SMR, MP, USAR, INOD, OPEN, TTD, DKNG, and ABNB [2]. Group 3: New Listings - On November 4, a new stock from the electric aircraft manufacturer $BETA will be listed [2]. - On November 6, two companies, 文远知行 and 小马智行, will be listed on the Hong Kong Stock Exchange [2]. - On November 7, new stocks from children's English education company MKTR and gaming company LBRJ will be listed [2]. Group 4: Significant Events - On November 7, Tesla's shareholder meeting will take place, where a $1 trillion compensation plan will be voted on, and a potential Gen 3 robot release is expected [2]. - The timing for the release of the October non-farm payroll data is pending due to the government shutdown [2].